Elioda Tumwesigye

Last updated

Elioda Tumwesigye
Elioda.jpg
Born (1964-04-05) 5 April 1964 (age 59)
Sheema District, Uganda
NationalityUgandan
Citizenship Uganda
Alma mater Makerere University
(Bachelor of Medicine and Bachelor of Surgery)
Case Western Reserve University
(Master of Science in epidemiology)
Occupation(s) Physician, Epidemiologist, Politician
Years activesince 1990
Known for Politics
Title Cabinet Minister
SpouseJustine Tumwesigye

Elioda Tumwesigye is a Ugandan politician, physician, and epidemiologist who has served as minister of science, technology and innovation in the cabinet of Uganda since June 2016. [1] From March 2015 until June 2016, he served as the minister of health. [2]

Contents

Tumwesigye has been the elected member of parliament representing Sheema Municipality in Sheema District, since 2018. [3] From 25 July 2013 to 28 February 2015, he served as state minister for health (general duties). [4] He was promoted to minister of health on 1 March 2015, [5] taking a slot left vacant since 18 September 2014. [6]

Background and education

Tumwesigye was born in Sheema District on 5 April 1964 to Yekonia and Edinance Kasyamutwe. He was their second child. He attended Ntare School for his O-Level education, graduating in 1981, and for his A-Level studies where he was elected Head Boy and later graduated in 1984 as the third best performing student in the country. He obtained a Bachelor of Medicine and Bachelor of Surgery degree from Makerere University in 1990. While attending Makerere, he started the Sheema University Student's Association, which was still active as of March 2015. He was also elected health secretary of University Hall, a men's hall of residence at Makerere. In 1997, he obtained a Master of Science in epidemiology from Case Western Reserve University. [7]

Early career

From 1990 until 2001, he worked as a medical officer at the Uganda Ministry of Health, serving in the Epidemiology Studies Unit during the last four years. In 2001, he contested the parliamentary seat of Sheema County North, in Sheema District, on the National Resistance Movement political party ticket. He won and was re-elected in 2006 and 2011. [7]

Research

Through his career as a physician and epidemiologist, he has made substantial contribution through his research that is mostly about viral diseases which are published in some of the best journals in the world. Some of the articles include; Characteristics of human encounters and social mixing patterns relevant to infectious diseases spread by close contact: a survey in Southwest Uganda. This study provided detailed information on contact patterns and their spatial characteristics in an African setting. [8] An intervention to support HIV pre-exposure prophylaxis (PrEP) adherence in HIV serodiscordant couples in Uganda. This study established that PrEP adherence intervention was feasible in a clinical trial of PrEP in Uganda and PrEP adherence increased after the intervention. [9] Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study. The data from this study reassured that oral PrEP delivery to women can continue without the need for concurrent testing for bacterial vaginosis or vaginal dysbiosis. [10] Low risk of Proximal Tubular Dysfunction associated with Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in men and women. the study found that daily oral FTC-TDF PrEP was not significantly associated with tubulopathy over the course of 24 months, nor did tubulopathy predict clinically relevant eGFR decline. [11] Adherence to HIV antiretroviral therapy among pregnant and postpartum women during the Option B+ era: 12-month cohort study in urban South Africa and rural Uganda. [12] Household-Based HIV counseling and testing as a platform for referral to HIV care and medical male circumcision in Uganda: A pilot evaluation. [13] Delay of antiretroviral therapy initiation is common in East African HIV-infected individuals in Serodiscordant partnerships. [14] Successful discontinuation of the Placebo Arm and provision of an effective HIV prevention product after a positive interim efficacy result: the Pprtners PrEP study experience. [15] Effect of home-based HIV counselling and testing on stigma and risky sexual behaviours: serial cross-sectional studies in Uganda. [16] Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. [17] What's love got to do with It? explaining adherence to oral Antiretroviral Pre-exposure Prophylaxis (PrEP) for HIV Serodiscordant couples. [18] Lay social resources for support of adherence to Antiretroviral Prophylaxis for HIV prevention among Serodiscordant couples in sub-Saharan Africa: a qualitative study. [19] Adherence to Antiretroviral Prophylaxis for HIV prevention: A substudy cohort within a clinical Trial of Serodiscordant couples in East Africa. The study established that low PrEP adherence was associated with sexual behavior, alcohol use, younger age, and length of PrEP use. [20] Others are risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-Agent Preexposure Prophylaxis. [21] Intimate partner violence and adherence to HIV Pre-exposure Prophylaxis (PrEP) in African women in HIV Serodiscordant relationships: A prospective cohort study. [22]

See also

Related Research Articles

Post-exposure prophylaxis, also known as post-exposure prevention (PEP), is any preventive medical treatment started after exposure to a pathogen in order to prevent the infection from occurring.

<span class="mw-page-title-main">Emtricitabine/tenofovir</span> Drug combination for HIV/AIDS prophylaxis and treatment

Emtricitabine/tenofovir, sold under the brand name Truvada among others, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS. It contains the antiretroviral medications emtricitabine and tenofovir disoproxil. For treatment, it must be used in combination with other antiretroviral medications. For prevention before exposure, in those who are at high risk, it is recommended along with safer sex practices. It does not cure HIV/AIDS. Emtricitabine/tenofovir is taken by mouth.

<span class="mw-page-title-main">Pre-exposure prophylaxis</span> HIV prevention strategy using preventative medication for HIV-negative individuals

Pre-exposure prophylaxis (PrEP) is the use of medications to prevent the spread of disease in people who have not yet been exposed to a disease-causing agent, usually a virus. The term typically refers to the use of antiviral drugs as a strategy for the prevention of HIV/AIDS. PrEP is one of a number of HIV prevention strategies for people who are HIV negative but who have a higher risk of acquiring HIV, including sexually active adults at increased risk of contracting HIV, people who engage in intravenous drug use, and serodiscordant sexually active couples.

<span class="mw-page-title-main">HIV Prevention Trials Network</span>

The HIV Prevention Trials Network (HPTN) is a worldwide collaborative clinical trials network that brings together investigators, ethicists, community and other partners to develop and test the safety and efficacy of interventions designed to prevent the acquisition and transmission of HIV. HPTN studies evaluate new HIV prevention interventions and strategies in populations and geographical regions that bear a disproportionate burden of infection. The HPTN is committed to the highest ethical standards for its clinical trials and recognizes the importance of community engagement in all phases of the research process.

iPrEx

iPrEx was a phase III clinical trial to determine whether the antiretroviral medication emtricitabine/tenofovir could safely and effectively prevent HIV acquisition through sex in men who have sex with men and transgender women. iPrEx was the first human study of an HIV prevention strategy known as pre-exposure prophylaxis, or PrEP.

CONRAD is a non-profit organization scientific research organization that works to improve the reproductive health of women, especially in developing countries. CONRAD was established in 1986 under a cooperative agreement between Eastern Virginia Medical School (EVMS) and the United States Agency for International Development(USAID). CONRAD’s products are developed primarily for women in low-resource settings, in that they are designed to be safe, affordable and user-friendly. CONRAD is led by Scientific and Executive Director Gustavo Doncel, M.D., Ph.D. Primary funding for CONRAD comes from the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Agency for International Development (USAID), with additional funding from The Bill & Melinda Gates Foundation and the National Institutes of Health (NIH).

HIV prevention refers to practices that aim to prevent the spread of the human immunodeficiency virus (HIV). HIV prevention practices may be undertaken by individuals to protect their own health and the health of those in their community, or may be instituted by governments and community-based organizations as public health policies.

A rectal microbicide is a microbicide for rectal use. Most commonly such a product would be a topical gel inserted into the anus so that it make act as protection against the contract of a sexually transmitted infection during anal sex.

<span class="mw-page-title-main">Anand Reddi</span>

Anand Reddi is a researcher and global health specialist. He is known for his scholarly work on U.S. Global Health Policy including the President's Emergency Plan for AIDS Relief (PEPFAR). His basic science research focuses on the molecular mechanisms involved in skin squamous cell cancer tumor initiation and metastasis. In 2005, Reddi was a Fulbright Scholar to South Africa. He served on the board of directors of the AIDS Healthcare Foundation from 2009–11 and is currently on the board of directors of the Bay Area Global Health Alliance.

Harriet Mayanja-Kizza, MBChB, MMed, MSc, FACP, is a Ugandan physician, researcher, and academic administrator. She is the former Dean of Makerere University School of Medicine, the oldest medical school in East Africa, established in 1924.

Treatment as prevention (TasP) is a concept in public health that promotes treatment as a way to prevent and reduce the likelihood of HIV illness, death and transmission from an infected individual to others. Expanding access to earlier HIV diagnosis and treatment as a means to address the global epidemic by preventing illness, death and transmission was first proposed in 2000 by Garnett et al. The term is often used to talk about treating people that are currently living with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) to prevent illness, death and transmission. Although some experts narrow this to only include preventing infections, treatment prevents illnesses such as tuberculosis and has been shown to prevent death. In relation to HIV, antiretroviral therapy (ART) is a three or more drug combination therapy that is used to decrease the viral load, or the measured amount of virus, in an infected individual. Such medications are used as a preventative for infected individuals to not only spread the HIV virus to their negative partners but also improve their current health to increase their lifespans. When taken correctly, ART is able to diminish the presence of the HIV virus in the bodily fluids of an infected person to a level of undetectability. Consistent adherence to an ARV regimen, monitoring, and testing are essential for continued confirmed viral suppression. Treatment as prevention rose to great prominence in 2011, as part of the HPTN 052 study, which shed light on the benefits of early treatment for HIV positive individuals.

M. Juliana “Julie” McElrath is a senior vice president and director of the vaccine and infection disease division at Fred Hutchinson Cancer Research Center and the principal investigator of the HIV Vaccine Trials Network Laboratory Center in Seattle, Washington. She is also a professor at the University of Washington.

<span class="mw-page-title-main">Islatravir</span> Chemical compound

Islatravir is an investigational drug for the treatment of HIV infection. It is classified as a nucleoside reverse transcriptase translocation inhibitor (NRTTI). Merck is developing a subdermal drug-eluting implant to administer islatravir.

Lisa M. Frenkel is an American pediatrician currently Professor at University of Washington and an Elected Fellow of the American Association for the Advancement of Science.

Elizabeth Anne Bukusi FAAS is a research professor working within the field of obstetrics and gynaecology, and global health. Bukusi's main areas of research focus around sexually transmitted infections, women's health, reproductive health, and HIV care, prevention and treatment. Bukusi is the Chief Research Officer at the Kenya Medical Research Institute (KEMRI) and led a "landmark" study on the use of PrEP in Kenya.

In January 2018, the provincial government of British Columbia (BC) began providing individuals at high risk of HIV infection with pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) at no cost. High risk individuals include men and trans women who have sex with men, people who inject drugs, and people who have sex with people living with HIV. One year following this policy change, which is delivered as part of the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE)'s Drug Treatment Program, almost 3,300 people have been prescribed with PrEP or PEP.

Sarah Fidler is an immunologist, researcher and professor in HIV Medicine at Imperial College London and consultant physician in HIV for St Mary's Hospital, London.

Julia Lenore Marcus is an American public health researcher and infectious disease epidemiologist at Harvard Medical School. Her research focuses on improving the implementation of pre-exposure prophylaxis (PrEP) for HIV prevention in the United States. Marcus is also a popular science communicator, and has contributed to The Atlantic.

Damalie Nakanjako, is a Ugandan specialist physician, internist, immunologist, infectious diseases consultant, academic and researcher, who serves as the Principal and Professor of Medicine at Makerere University College of Health Sciences. Immediately prior to her present position, she served as Dean of Makerere University School of Medicine, from 2019 until 17 February 2021.

Nelly Mugo is a Kenyan obstetrician, gynaecologist and scientist involved in HIV and cervical cancer prevention research. She is a Research Associate Professor, Global Health in the University of Washington and the Center for Clinical Research, Kenya Medical Research Institute. She is also a member of the African Academy of Sciences. In 2021, Mugo became the inaugural recipient of the Gita Ramjee Prize.

References

  1. ↑ Uganda State House (6 June 2016). "Museveni's new cabinet list At 6 June 2016" (PDF). Daily Monitor . Kampala. Archived from the original (PDF) on 7 October 2016. Retrieved 6 June 2016.
  2. ↑ Presidential Press Unit (1 March 2015). "President Museveni announces new Cabinet". Entebbe: Uganda State House. Retrieved 15 June 2016.
  3. ↑ "Tumwesigye wins Sheema municipality MP race". Daily Monitor. Retrieved 23 April 2019.
  4. ↑ Nakajubi, Gloria (25 July 2013). "New Health Minister Tumwesigye Reports for Work". New Vision (Kampala). Retrieved 1 March 2015.
  5. ↑ Uganda State House (1 March 2015). "Full Cabinet List As At 1 March 2015" (PDF). Daily Monitor (Kampala). Archived from the original (PDF) on 9 July 2017. Retrieved 1 March 2015.
  6. ↑ Newvision, Reporter (19 September 2014). "Ruhakana Rugunda New Prime Minister". New Vision (Kampala). Archived from the original on 10 May 2015. Retrieved 19 September 2014.
  7. 1 2 POU. "Profile of Tumwesigye Elioda, Member of Parliament for Sheema County North, Sheema District". Parliament of Uganda (POU). Archived from the original on 23 October 2015. Retrieved 1 March 2015.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  8. ↑ le Polain de Waroux, O.; Cohuet, S.; Ndazima, D.; Kucharski, A. J.; Juan-Giner, A.; Flasche, S.; Tumwesigye, E.; Arinaitwe, R.; Mwanga-Amumpaire, J.; Boum, Y.; Nackers, F.; Checchi, F.; Grais, R. F.; Edmunds, W. J. (11 April 2018). "Characteristics of human encounters and social mixing patterns relevant to infectious diseases spread by close contact: a survey in Southwest Uganda". BMC Infectious Diseases. 18 (1): 172. doi:10.1186/s12879-018-3073-1. ISSN   1471-2334. PMC   5896105 . PMID   29642869.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  9. ↑ Psaros, Christina; Haberer, Jessica E.; Katabira, Elly; Ronald, Allan; Tumwesigye, Elioda; Campbell, James D.; Wangisi, Jonathan; Mugwanya, Kenneth; Kintu, Alex; Enyakoit, Michael; Thomas, Katherine K.; Donnell, Deborah; Krows, Meighan; Kidoguchi, Lara; Ware, Norma (15 August 2014). "An Intervention to Support HIV Preexposure Prophylaxis Adherence in HIV-Serodiscordant Couples in Uganda". Journal of Acquired Immune Deficiency Syndromes. 66 (5): 522–529. doi:10.1097/QAI.0000000000000212. ISSN   1525-4135. PMC   4191829 . PMID   24853311.
  10. ↑ Heffron, Renee; McClelland, R Scott; Balkus, Jennifer E; Celum, Connie; Cohen, Craig R; Mugo, Nelly; Bukusi, Elizabeth; Donnell, Deborah; Lingappa, Jairam; Kiarie, James; Fiedler, Tina; Munch, Matthew; Fredricks, David N; Baeten, Jared M; Celum, Connie (1 October 2017). "Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study". The Lancet HIV. 4 (10): e449–e456. doi:10.1016/S2352-3018(17)30110-8. ISSN   2352-3018. PMC   5649365 . PMID   28732773.
  11. ↑ Mugwanya, Kenneth (2016). "Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women". Journal of Infectious Diseases. pp. 1050–1057. doi:10.1093/infdis/jiw125. PMC   5021224 . PMID   27029778 . Retrieved 31 January 2023.
  12. ↑ Matthews, Lynn T; Orrell, Catherine; Bwana, Mwebesa Bosco; Tsai, Alexander C; Psaros, Christina; Asiimwe, Stephen; Amanyire, Gideon; Musinguzi, Nicholas; Bell, Kathleen; Bangsberg, David R; Haberer, Jessica E; the META Study Investigators; April, Nomakhaya; Mpahleni, Alienah; Situlo, Vivie (2020). "Adherence to HIV antiretroviral therapy among pregnant and postpartum women during the Option B+ era: 12‐month cohort study in urban South Africa and rural Uganda". Journal of the International AIDS Society. 23 (8): e25586. doi:10.1002/jia2.25586. ISSN   1758-2652. PMC   7441010 . PMID   32820622.
  13. ↑ Tumwebaze, Henry; Tumwesigye, Elioda; Baeten, Jared M.; Kurth, Ann E.; Revall, Jennifer; Murnane, Pamela M.; Chang, Larry W.; Celum, Connie (13 December 2012). "Household-Based HIV Counseling and Testing as a Platform for Referral to HIV Care and Medical Male Circumcision in Uganda: A Pilot Evaluation". PLOS ONE. 7 (12): e51620. Bibcode:2012PLoSO...751620T. doi: 10.1371/journal.pone.0051620 . ISSN   1932-6203. PMC   3521653 . PMID   23272125.
  14. ↑ Mujugira, Andrew; Celum, Connie; Thomas, Katherine K.; Farquhar, Carey; Mugo, Nelly; Katabira, Elly; Bukusi, Elizabeth A.; Tumwesigye, Elioda; Baeten, Jared M. (1 August 2014). "Delay of Antiretroviral Therapy Initiation Is Common in East African HIV-Infected Individuals in Serodiscordant Partnerships". Journal of Acquired Immune Deficiency Syndromes. 66 (4): 436–442. doi:10.1097/QAI.0000000000000192. ISSN   1525-4135. PMC   4077929 . PMID   24798765.
  15. ↑ Ndase, Patrick; Celum, Connie; Campbell, James; Bukusi, Elizabeth; Kiarie, James; Katabira, Elly; Mugo, Nelly; Tumwesigye, Elioda; Wangisi, Jonathan; Were, Edwin; Brantley, Justin; Donnell, Deborah; Baeten, Jared M. (1 June 2014). "Successful Discontinuation of the Placebo Arm and Provision of an Effective HIV Prevention Product After a Positive Interim Efficacy Result: The Partners PrEP Study Experience". Journal of Acquired Immune Deficiency Syndromes. 66 (2): 206–212. doi: 10.1097/QAI.0000000000000141 . ISSN   1525-4135. PMID   24828268. S2CID   38969652.
  16. ↑ Nuwaha, Fred; Kasasa, Simon; Wana, Godwill; Muganzi, Elly; Tumwesigye, Elioda (4 June 2012). "Effect of home-based HIV counselling and testing on stigma and risky sexual behaviours: serial cross-sectional studies in Uganda". Journal of the International AIDS Society. 15 (2): 17423. doi:10.7448/IAS.15.2.17423. ISSN   1758-2652. PMC   3499790 . PMID   22713257.
  17. ↑ Baeten, Jared M.; Donnell, Deborah; Ndase, Patrick; Mugo, Nelly R.; Campbell, James D.; Wangisi, Jonathan; Tappero, Jordan W.; Bukusi, Elizabeth A.; Cohen, Craig R.; Katabira, Elly; Ronald, Allan; Tumwesigye, Elioda; Were, Edwin; Fife, Kenneth H.; Kiarie, James (2 August 2012). "Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women". New England Journal of Medicine. 367 (5): 399–410. doi:10.1056/NEJMoa1108524. ISSN   0028-4793. PMC   3770474 . PMID   22784037.
  18. ↑ Ware, Norma C.; Wyatt, Monique A.; Haberer, Jessica E.; Baeten, Jared M.; Kintu, Alexander; Psaros, Christina; Safren, Steven; Tumwesigye, Elioda; Celum, Connie L.; Bangsberg, David R. (15 April 2012). "What's Love Got to Do With It? Explaining Adherence to Oral Antiretroviral Pre-Exposure Prophylaxis for HIV-Serodiscordant Couples". Journal of Acquired Immune Deficiency Syndromes. 59 (5): 463–468. doi:10.1097/QAI.0b013e31824a060b. ISSN   1525-4135. PMC   3826169 . PMID   22267018.
  19. ↑ Ware, Norma C.; Pisarski, Emily E.; Haberer, Jessica E.; Wyatt, Monique A.; Tumwesigye, Elioda; Baeten, Jared M.; Celum, Connie L.; Bangsberg, David R. (1 May 2015). "Lay Social Resources for Support of Adherence to Antiretroviral Prophylaxis for HIV Prevention Among Serodiscordant Couples in sub-Saharan Africa: A Qualitative Study". AIDS and Behavior. 19 (5): 811–820. doi:10.1007/s10461-014-0899-4. ISSN   1573-3254. PMC   4415942 . PMID   25267114.
  20. ↑ Haberer, Jessica E.; Baeten, Jared M.; Campbell, James; Wangisi, Jonathan; Katabira, Elly; Ronald, Allan; Tumwesigye, Elioda; Psaros, Christina; Safren, Steven A.; Ware, Norma C.; Thomas, Katherine K.; Donnell, Deborah; Krows, Meighan; Kidoguchi, Lara; Celum, Connie (10 September 2013). "Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa". PLOS Medicine. 10 (9): e1001511. doi:10.1371/journal.pmed.1001511. ISSN   1549-1676. PMC   3769210 . PMID   24058300.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  21. ↑ Lehman, Dara A. (2015). "Risk of Drug Resistance Among Persons Acquiring HIV Within a Randomized Clinical Trial of Single- or Dual-Agent Preexposure Prophylaxis". Journal of Infectious Diseases. pp. 1211–1218. doi:10.1093/infdis/jiu677. PMC   4402339 . PMID   25587020 . Retrieved 31 January 2023.
  22. ↑ Roberts, Sarah T.; Haberer, Jessica; Celum, Connie; Mugo, Nelly; Ware, Norma C.; Cohen, Craig R.; Tappero, Jordan W.; Kiarie, James; Ronald, Allan; Mujugira, Andrew; Tumwesigye, Elioda; Were, Edwin; Irungu, Elizabeth; Baeten, Jared M.; for the Partners PrEP Study Team (1 November 2016). "Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study". Journal of Acquired Immune Deficiency Syndromes. 73 (3): 313–322. doi:10.1097/QAI.0000000000001093. ISSN   1525-4135. PMC   5065369 . PMID   27243900.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.